Akebia Therapeutics (AKBA) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
August 12, 2024 6:13 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $7.50 (from $6.00) while maintaining a Buy rating.
The analyst comments "Akebia is focused on the long game, with pre-commercial execution preparing for Vafseo as the standard-of-care. As previously announced, Akebia submitted its TDAPA application in June. Akebia expects to have a CPT code assigned in October 2024 and full TDAPA designation by January 1, 2025. In... More
